The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Open accessAbstract
Treatments that target immune checkpoints, such as the one mediated by programmed cell death protein 1 (PD-1) and its ligand PD-L1, have been approved for treating human cancers with durable clinical benefit. However, many patients with cancer fail to respond to compounds that target the PD-1 and PD-L1 interaction, and the underlying mechanism(s) is not well understood. Recent studies revealed that response to PD-1-PD-L1 blockade might correlate with PD-L1 expression levels in tumour cells. Hence, it is important to understand the mechanistic pathways that control PD-L1 protein expression and stability, which can offer a molecular basis to improve the clinical response rate and efficacy of PD-1-PD-L1 blockade in patients with cancer. Here we show that PD-L1 protein abundance is regulated by cyclin D-CDK4 and the cullin 3-SPOP E3 ligase via proteasome-mediated degradation. Inhibition of CDK4 and CDK6 (hereafter CDK4/6) in vivo increases PD-L1 protein levels by impeding cyclin D-CDK4-mediated phosphorylation of speckle-type POZ protein (SPOP) and thereby promoting SPOP degradation by the anaphase-promoting complex activator FZR1. Loss-of-function mutations in SPOP compromise ubiquitination-mediated PD-L1 degradation, leading to increased PD-L1 levels and reduced numbers of tumour-infiltrating lymphocytes in mouse tumours and in primary human prostate cancer specimens. Notably, combining CDK4/6 inhibitor treatment with anti-PD-1 immunotherapy enhances tumour regression and markedly improves overall survival rates in mouse tumour models. Our study uncovers a novel molecular mechanism for regulating PD-L1 protein stability by a cell cycle kinase and reveals the potential for using combination treatment with CDK4/6 inhibitors and PD-1-PD-L1 immune checkpoint blockade to enhance therapeutic efficacy for human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, several critical proteins including CMTM4, CMTM6, GSK3β, CSN5, CDK4, CDK6, and palmitoylated B3GNT3 have been shown to affect post-translational PD-L1 stability31–36.”
From PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells (2022) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the Cullin 3-SPOP E3-ligase complex can directly ubiquitinate PD-L1 in a cell-cycle dependent manner, leading to its degradation [15].”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“First, as previously described [15], perturbation of the CUL3-SPOP complex interferes with the ubiquitination of PD-L1, directly enhancing its stability and protein expression level.”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“we verified that perturbation of BHLH transcription factor MYC [12] and the ubiquitin ligase CUL3 [15] both increased PD-L1 protein levels, consistent with previous reports.”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
In the citing paper
“CDK4 was shown to have kinase activity towards SPOP, a cullin 3 E3 ubiquitin ligase adaptor protein that can interact with PD-L1 (Zhang et al., 2018).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
In the citing paper
“Treatment with palbociclib inhibits SPOP phosphorylation, promoting its degradation and blocking PD-L1 proteasome mediated degradation.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
In the citing paper
“Combining palbociclib with a PD-1 blockade enhanced tumor regression and improved overall survival in mouse xenograft models of colon adenocarcinoma (Deng et al., 2017; Zhang et al., 2018).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,261
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A. A., Ahn, J., Akbani, R., Ally, A., Amin, S. B., Andry, C., Annala, M., Aprikian, A. G., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,126
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Self-citationTaxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,971
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Siciński, P. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,931
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J.-P. P., White, T. A., Stojanov, P., Allen, E. M. V., Stransky, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.2279 · Cited by 1,550
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,000
Mittal, A., Moltó, C., Tamimi, F., Schlam, I. M., Sammons, S. L., Tolaney, S. M., & Tarantino, P. (2023) · Cancers · doi:10.3390/cancers15072015 · Cited by 41
Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy
Yi, J., Tavana, O., Li, H., Wang, D., Baer, R. J., & Gu, W. J. (2023) · Nature Communications · doi:10.1038/s41467-023-37617-3 · Cited by 45
Fan, H., Liu, W., Zeng, Y., Zhou, Y., Gao, M., Yang, L., Liu, H., Shi, Y., Li, L., Ma, J., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05412-x · Cited by 39
Meng, F., Su, Y., & Xu, B. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12804 · Cited by 40
Jiang, H., Ma, Q., Zhong, M., Gao, H., Li, Y., & Hao, Y. (2021) · The Plant Journal · doi:10.1111/tpj.15191 · Cited by 39
CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
Chen, Y., Cai, Q., Pan, C., Liu, W., Li, L., Liu, J., Gao, M., Li, X., Wang, L., Rao, Y., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0806 · Cited by 37
NEDD8-conjugating enzyme E2s: critical targets for cancer therapy
Zhou, L., Lin, X., Zhu, J., Zhang, L., Chen, S., Yang, H., Jia, L., & Chen, B. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01337-w · Cited by 38
Luo, T., Fan, Z., Zeng, A., Wang, A., Pan, Y., Xu, Y., Chen, H., Chen, W., Nie, D., Lin, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202410427 · Cited by 38
Self-citationAPC/C Ubiquitin Ligase: Coupling Cellular Differentiation to G1/G0 Phase in Multicellular Systems
Kimata, Y. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.03.001 · Cited by 39
Knudsen, E. S., Shapiro, G. I., & Keyomarsi, K. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_281085 · Cited by 36
Domvri, K., Petanidis, S., Anestakis, D., Porpodis, Κ., Bai, C., Zarogoulidis, P., Freitag, L., Hohenforst‐Schmidt, W., & Katopodi, T. (2020) · Oncotarget · doi:10.18632/oncotarget.27675 · Cited by 39
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy
Li, X.-M., Zhao, Z., Xiao, Y., Xia, Q., Zhou, P., Wang, S., Wu, H., & Hu, J. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00394-2 · Cited by 40
CSN6‐SPOP‐HMGCS1 Axis Promotes Hepatocellular Carcinoma Progression via YAP1 Activation
Li, K., Zhang, J., Lyu, H., Yang, J., Wei, W., Wang, Y., Luo, H., Zhang, Y., Jiang, X. J., Yi, H., et al. (2024) · Advanced Science · doi:10.1002/advs.202306827 · Cited by 36
Self-citationGetting under the skin: The role of CDK4/6 in melanomas
Guo, L., Qi, J., Wang, H., Jiang, X. L., & Liu, Y. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112531 · Cited by 37
Self-citationSearching for the real function of mTOR signaling in the regulation of PD-L1 expression
Sun, S. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100847 · Cited by 38
Zhang, Y. F., Zhang, Z. H., Li, M. Y., Wang, J. Y., Xing, Y., Ri, M., Jin, C. H., Xu, G. H., Piao, L. X., Zuo, H. X., et al. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153425 · Cited by 36
Lawal, B., Lin, L.-C., Lee, J., Chen, J.-H., Bekaii‐Saab, T., Wu, A. T. H., & Ho, C. (2021) · Cancers · doi:10.3390/cancers13050954 · Cited by 38
Yu, T., Nie, W., Hong, Z., He, Y., Chen, J., Mi, X., Yang, S., Li, X., Wang, B., Lin, Y., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100715 · Cited by 38
The clinical and molecular significance associated with STING signaling in breast cancer
Parkes, E. E., Humphries, M. P., Gilmore, E. S., Sidi, F. A., Bingham, V., Phyu, S. M., Craig, S. G., Graham, C., Miller, J. J., Griffin, D., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00283-z · Cited by 37
Chui, N. N., Cheu, J. W., Yuen, V. W., Chiu, D. K., Goh, C., Lee, D. P. H., Zhang, M. S., Ng, I. O., & Wong, C. C. (2021) · Hepatology Communications · doi:10.1002/hep4.1682 · Cited by 38
Lin, C., Huang, K., Kao, S.-H., Lin, M.-S., Lin, C.-C., Yang, S., Chung, W.-C., Chang, Y.-H., Chein, R., & Yang, P. (2023) · Science Advances · doi:10.1126/sciadv.ade9944 · Cited by 37
Noh, J., Lee, I. P., Han, N. R., Kim, M., Min, Y. K., Lee, S.-Y., Yun, S. H., Kim, S. I., Park, T., Chung, H., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.07.005 · Cited by 36
Regulation of PD-L1 Trafficking from Synthesis to Degradation
Lemma, E. Y., Letian, A., Altorki, N. K., & McGraw, T. E. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0953 · Cited by 40
Zhang, R., Wang, J., Du, Y., Yu, Z., Wang, Y., Jiang, Y., Wu, Y., Le, T., Li, Z., Zhang, G., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007529 · Cited by 36
Shi, L., Yan, Y., He, Y., Yan, B., Pan, Y., Orme, J. J., Zhang, J., Xu, W., Pang, J., & Huang, H. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3258 · Cited by 36
Self-citationZhu, J., Huang, R., Yang, R., Xiao, Y., Yan, J., Zheng, C., Xiao, W., Huang, C., & Wang, Y. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02223-0 · Cited by 37
Emerging role of PD-L1 modification in cancer immunotherapy.
Hu, X., Lin, Z., Wang, Z. P., & Zhou, Q. (2021) · PubMed Central · Cited by 36
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
Li, Z., Sun, G., Sun, G., Cheng, Y., Wu, L., Wang, Q., Lv, C., Zhou, Y., Xia, Y., & Tang, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.771335 · Cited by 37
Acetylation in pathogenesis: Revealing emerging mechanisms and therapeutic prospects
Jiang, N., Li, W., Jiang, S., Xie, M., & Liu, R. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115519 · Cited by 38
CDK4/6 inhibitors in lung cancer: current practice and future directions
Lv, S., Yang, J., Lin, J., Huang, X., Zhao, H., Zhao, C., & Yang, L. (2024) · European Respiratory Review · doi:10.1183/16000617.0145-2023 · Cited by 35
Cao, Y., Li, X., Kong, S., Shang, S., & Qi, Y. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15156 · Cited by 35
RetractedIdentification of the Prognostic Value of Immune-Related Genes in Esophageal Cancer
Guo, X., Wang, Y., Zhang, H., Qin, C., Cheng, A., Liu, J., Dai, X., & Wang, Z. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00989 · Cited by 35
Self-citationA20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
Guo, W., Ma, J., Guo, S., Wang, H., Wang, S., Shi, Q., Liu, L., Zhao, T., Yang, F., Chen, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001866 · Cited by 35
Self-citationJin, X., Qing, S., Li, Q., Zhuang, H., Shen, L., Li, J., Qi, H., Lin, T., Lin, Z.-H., Wang, J., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab489 · Cited by 36
Dall’Acqua, A., Bartoletti, M., Masoudi-Khoram, N., Sorio, R., Puglisi, F., Belletti, B., & Baldassarre, G. (2021) · Cancers · doi:10.3390/cancers13123035 · Cited by 37
MiR-93-5p regulates tumorigenesis and tumor immunity by targeting PD-L1/CCND1 in breast cancer
Yang, M., Xiao, R., Wang, X., Xiong, Y., Duan, Z., Li, D., & Kan, Q. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-97 · Cited by 35
Yousuf, M., Alam, M., Shamsi, A., Κhan, P., Hasan, G. M., Haque, Q. M. R., & Hassan, M. I. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.07.156 · Cited by 36
Ma, J., Shi, Q., Cui, G., Sheng, H., Botuyan, M. V., Zhou, Y., Yan, Y., He, Y., Wang, L., Wang, Y. Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26049-6 · Cited by 34
Immunomodulatory effects of CDK4/6 inhibitors
Zhang, S., Xu, Q., Sun, W., Zhou, J., & Zhou, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188912 · Cited by 34
Yu, Z., Wu, X., Zhu, J., Yan, H., Li, Y., Zhang, H., Zhong, Y., Lin, M., Ye, G., Li, X., et al. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05144-z · Cited by 34
Xiang, B., Zhang, M., Li, K., Zhang, Z., Liu, Y., Gao, M., Wang, X., Xiao, X., Sun, Y., He, C. H., et al. (2025) · Nature Immunology · doi:10.1038/s41590-024-02047-w · Cited by 34
Self-citationPD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer
Zhu, H., Du, C., Yuan, M., Fu, P., He, Q., Yang, B., & Cao, J. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.006 · Cited by 36
G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer
Mukhopadhyay, C., Yang, C., Xu, L., Liu, D., Wang, Y., Huang, D., Deonarine, L. D., Cyrta, J., Davicioni, E., Sboner, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27024-x · Cited by 35
Pesch, A. M., Hirsh, N. H., Michmerhuizen, A. R., Jungles, K. M., Wilder-Romans, K., Chandler, B. C., Liu, M., Lerner, L. M., Nino, C. A., Ward, C., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.154402 · Cited by 33
Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity
Wang, H., Fan, Y., Chen, W., Lv, Z., Wu, S., Xuan, Y., Wang, C., Lu, Y., Guo, T., Shen, D., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.2011673 · Cited by 32
Self-citationEmerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
Ding, P., Ma, Z., Fan, Y., Feng, Y., Shao, C., Pan, M., Zhang, Y., Huang, D., Han, J. Y., Hu, Y., et al. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.01.002 · Cited by 37
Huang, L., LaBonte, M. J., Craig, S. G., Finn, S. P., & Allott, E. H. (2022) · Cancers · doi:10.3390/cancers14061367 · Cited by 34
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
Lelliott, E. J., Sheppard, K. E., & McArthur, G. A. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00273-9 · Cited by 34
Anti‐tumour potential of PD‐L1 / PD ‐1 post‐translational modifications
Zhou, S., Zhu, J., Xu, J., Gu, B., Zhao, Q., Luo, C., Gao, Z., Chin, Y. E., & Cheng, X. (2022) · Immunology · doi:10.1111/imm.13573 · Cited by 38
Sollena, P., Nikolaou, V. A., Kotteas, E. A., Stratigos, A., Fattore, D., Orlandi, A., Mannino, M., Pumpo, M. D., Fida, M., Starace, M. V. R., et al. (2023) · Cancers · doi:10.3390/cancers15143658 · Cited by 35
Sharifi, M. N., Anandan, A., Grogan, P. T., & O'Regan, R. M. (2020) · Cancer · doi:10.1002/cncr.32931 · Cited by 36
The functional analysis of Cullin 7 E3 ubiquitin ligases in cancer
Shi, L., Du, D., Peng, Y., Liu, J., & Long, J. (2020) · Oncogenesis · doi:10.1038/s41389-020-00276-w · Cited by 33
How selective are clinical CDK4/6 inhibitors?
Hendrychová, D., Jorda, R., & Kryštof, V. (2020) · Medicinal Research Reviews · doi:10.1002/med.21769 · Cited by 36
Qin, Z., Hu, H., Sun, W. C., Chen, L., Jin, S., Xu, Q., Liu, Y., Yu, L., & Zeng, S. (2021) · Cancers · doi:10.3390/cancers13040618 · Cited by 34
Sun, W., Cui, J., Ge, Y., Wang, J., Yu, Y., Han, B., & Liu, B. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00919-4 · Cited by 33
The future of targeted kinase inhibitors in melanoma
Caksa, S., Baqai, U., & Aplin, A. E. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108200 · Cited by 37
Zou, Q., Liu, M., Liu, K., Zhang, Y., North, B. J., & Wang, B. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00777-x · Cited by 31
Sante, G. D., Pagé, J., Jiao, X., Nawab, O., Cristofanilli, M., Skordalakes, E., & Pestell, R. G. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1615889 · Cited by 33
Lu, L., Gaffney, S. G., Cannataro, V. L., & Townsend, J. P. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104554 · Cited by 32
Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer
Vafaizadeh, V., & Barekati, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00162 · Cited by 34
Resolving Cell Cycle Speed in One Snapshot with a Live-Cell Fluorescent Reporter
Eastman, A. E., Chen, X., Hu, X., Hartman, A. A., Morales, A. M. P., Yang, C. L.-H., Lü, J., Kueh, H. Y., & Guo, S. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107804 · Cited by 34
The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer
Glorieux, C., Xia, X., & Huang, P. (2021) · Cancers · doi:10.3390/cancers13174426 · Cited by 33
Combination Approaches to Target PD-1 Signaling in Cancer
Moore, E. K., Strazza, M., & Mor, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927265 · Cited by 32
Targeting the Molecular and Immunologic Features of Leiomyosarcoma
Cope, B. M., Traweek, R. S., Lazcano, R., Keung, E. Z.-Y., Lazar, A. J., Roland, C. L., & Nassif, E. F. (2023) · Cancers · doi:10.3390/cancers15072099 · Cited by 33
Kohlmeyer, J. L., Lingo, J. J., Kaemmer, C. A., Scherer, A., Warrier, A., Voigt, E. M., Garay, J. A. R., McGivney, G. R., Brockman, Q. R., Tang, A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0749 · Cited by 35
Salminen, A. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102694 · Cited by 33
Decoding heterogeneous single-cell perturbation responses
Song, B., Liu, D., Dai, W., McMyn, N. F., Wang, Q., Yang, D., Krejčí, A., Vasilyev, A., Untermoser, N., Loregger, A., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01626-9 · Cited by 40
Lao, M., Zhang, X., Li, Z., Sun, K., Yang, H., Wang, S., He, L., Chen, Y., Zhang, H., Shi, J., et al. (2025) · 癌症：英文版 · doi:10.1002/cac2.70038 · Cited by 31
The RUNX1/RUNX1T1 network: translating insights into therapeutic options
Swart, L. E., & Heidenreich, O. T. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.11.005 · Cited by 32
Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
Yu, X., Li, W., Young, K. H., & Li, Y. (2021) · Biomedicines · doi:10.3390/biomedicines9111702 · Cited by 37
Tong, J., Tan, X., Song, X., Gao, M., Risnik, D., Hao, S., Ermine, K., Wang, P., Li, H., Huang, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3062 · Cited by 32
Self-citationBai, X., Chen, Y., Zou, M., Li, C., Zhang, Y., Li, M., Cheng, S., & Zhang, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c06871 · Cited by 31
PPARγ inhibited tumor immune escape by inducing PD‐L1 autophagic degradation
Gou, Q., Che, S., Chen, M., Chen, H., Shi, J., & Hou, Y. (2023) · Cancer Science · doi:10.1111/cas.15818 · Cited by 32
RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination
Zhang, Y., Zeng, L., Wang, M., Yang, Z., Zhang, H., Gao, L., Zhang, R., Liu, J., Shan, W., Chang, Y., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007313 · Cited by 32
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer
Ziegler, D. V., Parashar, K., & Fajas, L. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.12.002 · Cited by 32
TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma
Wang, L., Liu, X., Han, Y., Tsai, H., Dan, Z., Yang, P., Xu, Z., Shu, F., He, C., Eriksson, J., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216861 · Cited by 30
Functional roles of Speckle-Type Poz (SPOP) Protein in Genomic stability
Wei, X., Fried, J. S., Li, Y., Hu, L., Gao, M. J., Zhang, S., & Xu, B. (2018) · Journal of Cancer · doi:10.7150/jca.25930 · Cited by 30
Shu, Z., Li, Z., Huang, H., Chen, Y., Fan, J., Yu, L., Wu, Z., Tian, L., Qi, Q., Peng, S., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01403-y · Cited by 31
Jang, H.-J., Truong, C., Lo, E. M., Holmes, H. M., Ramos, D., Ramineni, M., Lee, J., Wang, D. Y., Pietropaolo, M., Ripley, R. T., et al. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2021.08.054 · Cited by 30
The effect of hypoxia on PD-L1 expression in bladder cancer
Smith, V., Mukherjee, D., Lunj, S., Choudhury, A., Hoskin, P., West, C., & Illidge, T. (2021) · BMC Cancer · doi:10.1186/s12885-021-09009-7 · Cited by 30
Nassif, E. F., Cope, B. M., Traweek, R. S., Witt, R. G., Erstad, D. J., Scally, C. P., Thirasastr, P., Zarzour, M. A., Ludwig, J. A., Benjamin, R. S., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.33956 · Cited by 30
Kim, H., Choi, J., & Lee, K. (2022) · Biomedicines · doi:10.3390/biomedicines10051130 · Cited by 30
Mangolini, M., Maiqués-Díaz, A., Charalampopoulou, S., Hartmann, E., Bloehdorn, J., Moore, A., Giachetti, G., Lu, J., Franklin, V. N. R., Chilamakuri, C. S. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33739-2 · Cited by 31
Meta-analysis of tumor and T cell intrinsic mechanisms of sensitization to checkpoint inhibitionPreprint
Litchfield, K., Reading, J. L., Puttick, C., Abbosh, C., Bentham, R. B., Watkins, T. B. K., Rosenthal, R., Biswas, D., Lim, E. L., Bakir, M. A., et al. (2020) · doi:10.21203/rs.3.rs-76468/v1 · Cited by 32
Roles of ubiquitination in the crosstalk between tumors and the tumor microenvironment (Review)
Zhang, X., Meng, T., Cui, S., Liu, D., Pang, Q., & Wang, P. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5374 · Cited by 30
Geng, C., Zhang, M.-C., Manyam, G. C., Vykoukal, J. V., Fahrmann, J. F., Peng, S., Wu, C., Park, S., Kondraganti, S., Wang, D., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1439 · Cited by 33
Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Wang, S., Zhou, D., Xu, Z., Song, J., Qian, X., Lv, X., & Luan, J. (2019) · Current Drug Targets · doi:10.2174/1389450120666190402145325 · Cited by 29
Cullin 3 and Its Role in Tumorigenesis
Chen, R. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1025-0_12 · Cited by 29
Li, Y., Cao, X., Tian, C., & Zheng, J. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.04.015 · Cited by 29
Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma
Sager, R., Backe, S. J., Ahanin, E. F., Smith, G., Nsouli, I. S., Woodford, M. R., Bratslavsky, G., Bourboulia, D., & Mollapour, M. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00571-8 · Cited by 29
Li, X.-M., Wu, H., Xia, Q., Zhou, P., Wang, S., Xiao, Y., & Hu, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112882 · Cited by 32
Cellular Senescence in Hepatocellular Carcinoma: The Passenger or the Driver?
Cai, X., Guillot, A., & Liu, H. (2022) · Cells · doi:10.3390/cells12010132 · Cited by 31
Liang, J., Sun, G., Pan, X., Zhang, M., Shen, P., Zhu, S., Zhao, J., Zheng, L., Zhao, J., Chen, Y., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01182-7 · Cited by 28
Li, J., Xu, X., Xu, K., Zhou, X., Wu, K., Yao, Y., Liu, Z., Chen, C., Wang, L., Sun, Z., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03006-x · Cited by 28
PerturBase: a comprehensive database for single-cell perturbation data analysis and visualization
Wei, Z., Si, D., Duan, B., Gao, Y., Yu, Q., Zhang, Z., Guo, L., & Liu, Q. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae858 · Cited by 35
Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer
Brea, L. T., & Yu, J. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.12.003 · Cited by 28
Targeting PD-L1 Protein: Translation, Modification and Transport
Wei, R., Guo, L., Wang, Q., Miao, J., Kwok, H. F., & Lin, Y. (2018) · Current Protein and Peptide Science · doi:10.2174/1389203719666180928105632 · Cited by 28
CDK4 Inhibitors Thwart Immunity by Inhibiting Phospho-RB-NF-κB Complexes
Kim, S. J., Asfaha, S., & Dick, F. A. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.12.012 · Cited by 29
Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
Kase, A. M., Copland, J. A., & Tan, W. W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s266085 · Cited by 30
Ahn, R., & Ursini‐Siegel, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052608 · Cited by 30
Metadata
- Authors
- Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., Guo, J., Huang, Y.-H., Fan, C., Ren, S., Sun, Y., Freeman, G. J., Sicinski, P., & Wei, W.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Second Military Medical University (CN)
- Corresponding author
- Freeman, Gordon J.
- Wei, Wenyi
- ORCID
- Venue
- Nature
- Published
- 2017-11-16
- Volume
- 553
- Issue
- 7686
- Pages
- 91-95
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5754234
- OpenAlex
- W2769376007
- Cited by
- 1,013
- References
- 43
- Citations by year
- 2026: 81 · 2025: 123 · 2024: 138 · 2023: 140 · 2022: 134 · 2021: 157 · 2020: 118 · 2019: 78 · 2018: 43
- FWCI
- 28.82
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-07-03)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA190509, R01CA229307, R01CA200573, K99CA212292, R01CA177910, P50CA101942, R01CA132740, R01CA202634, P01CA080111, R01CA200651, R01CA083688)
- National Institute of General Medical Sciences (R01GM094777, R01GM089763)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- PD-L1, anti-PD-1 therapy, CDK4/6 inhibitors, FZR1, proteasomal degradation, polyubiquitination, tumor immune evasion, immune checkpoint blockade, combination immunotherapy, tumor immune microenvironment
- MeSH terms
- Animals, Cell Cycle, Cell Line, Female, Humans, Immunologic Surveillance, Male, Neoplasms, Nuclear Proteins, Phosphorylation, Prostatic Neoplasms, Repressor Proteins, Lymphocytes, Tumor-Infiltrating, Tumor Escape, Cullin Proteins, Proteasome Endopeptidase Complex, 14-3-3 Proteins, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Protein Stability, Cyclin D, Proteolysis, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Cdh1 Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
